Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients.
Sainz-Amo R, Rodero-Romero A, Monreal E, Chico-García JL, Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Veiga-González JL, de la Maza SS, Masjuan J, Costa-Frossard L, Villar LM.
Sainz-Amo R, et al. Among authors: de la maza ss.
Int J Mol Sci. 2024 Dec 7;25(23):13153. doi: 10.3390/ijms252313153.
Int J Mol Sci. 2024.
PMID: 39684862
Free PMC article.